FORT LAUDERDALE, FL / ACCESSWIRE / June 30, 2015 / The Automotive Resources Holding group (PINKSHEETS: ARNH) (“ARNH” or “the Company”) has won their appeal, from being wrongly named in a lawsuit. ARNH was wrongly named in a lawsuit by First Air Group, Inc. located in the state of NY. The case was heard under the laws of the state of NY and ARNH was not dropped from the suit in the lower courts. ARNH later perfected an appeal to overturn the findings of the lower court on July 25, 2014 where the Court of Appeal found in favor of ARNH and dismissed the company from any and all liability on April 2, 2015.

In addition to winning the appeal and being exonerated from all liability stemming from the First Air lawsuit, the company has been actively forming a new Board of Directors. “As the incoming CEO, and the first member of the Board of Directors of the company. I would like to personally thank the continued efforts of prior management, Ms. Kathy Roberton, to be more precise. Without her, intimate knowledge of the case, and hands on expertise, this would never have been possible. Kathy has shown high integrity and much regard for all shareholders and has been working with me to resolve any issues within the company,” stated CEO Mark Solomon.

More updates on the progress of the company will follow.

Mark S Solomon Esq.
CEO
954-463-6755
mark@marksolomonlaw.com

DISCLAIMER <<Caution Concerning Forward Looking Statements>>

This press release contains statements that are “Forward-Looking” in nature (within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). All statements regarding the Company’s financial position, potential, business strategy, plans and objectives for future operations are Forward-Looking statements. Many of these statements contain words such as “goal,” “aims,” “may,” “expect,” “believe,” “intend,” “anticipate,” “estimate,” “continue,” “would,” “exceed,” “should,” “steady,” “plan,” “potential,” “dramatic,” and variations of such words and similar expressions identify Forward-Looking statements, but their absence does not mean that a statement is not a Forward-Looking statement. Because Forward-Looking statements involve future risks and uncertainties, there are many factors that could cause actual results to differ materially from those expressed or implied. The Company cannot predict the actual effect these factors will have on its results and many of the factors and their effects are beyond the Company’s control. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or otherwise. Given these uncertainties, you should not rely too heavily on these forward-looking statements.

SOURCE: The Automotive Resource Network Holdings, Inc.

ReleaseID: 430268

VANCOUVER, BC / ACCESSWIRE / June 30, 2015 / Jemi Fibre Corp. (TSXV: JFI) (“Jemi Fibre” or the “Company”) is pleased to announce that it has completed the acquisition of Forest License A16832 (the “License”) as previously announced on March 3, 2015.

The License is located in the Kispiox Forest District in the vicinity of Hazelton, British Columbia and the acquisition was completed through an equal joint venture partnership with a British Columbia based, forestry company. The replaceable License has an annual allowable cut of 55,414 cubic meters plus a current undercut of 180,663 cubic metres. The Company anticipates commencing harvesting operations on the License area in the fall of 2015 and in connection with those operations, the Company will commence harvesting 4,000 acres of private timberland it owns in the Hazelton area. These private timberlands were acquired by the Company in connection with its reverse take-over of Dual Enterprises Ltd. in June 2013. 

The Company is also pleased to announce that it has entered into a five year agreement with the Northern Village of Beauval, located in northern Saskatchewan, to lease and operate a timber post peeling operation and to manage a Crown timber allocation providing for an annual harvest of 40,000 cubic metres. The timber supply for this facility will be maintained through co-operation with Carrier Forest Products, the North West Communities timber allocation, as well as the Company’s Crown timber allocation connected to its Aallcann operations. The Company and the North West Communities intend for this arrangement to provide the seven local communities with long-term, sustainable forestry job opportunities.

“We are pleased to increase our harvesting capacity and fibre supply with these transactions,” stated Mike Jenks, Chairman & CEO. “The Kispiox acquisition will enhance our ability to extract value from our own private timberlands in Hazelton and the Beauval agreement lines up our strategy of increasing production from our newly acquired Aallcann wood treatment facility in Saskatchewan.”

With these transactions, the Company expects to harvest over 1,450,000 cubic metres of timber on an annual basis, up 630% from the Company’s harvesting capacity prior to its acquisitions in June 2014.

For further information, please contact:

Brent Lokash, President
Tel: 1 604 428-1075
Email: brent.lokash@jemifibre.com

About Jemi Fibre
Jemi Fibre is a Western Canadian based forest products company which trades on the TSX Venture Exchange under the symbol JFI. Jemi Fibre’s operations consist of private timberlands and Crown forest licenses, a full service contract logging division, a sawmill producing high value lumber products and wood treatment facilities producing posts and lumber for agricultural use.

Forward Looking Statements
Certain statements included herein constitute forward-looking statements. The words “expect”, “intend”, “anticipate”, “propose” and “may” and similar expressions identify forward-looking statements. Forward-looking statements include, among other things, such risks, uncertainties and other factors set forth under “Risk Factors” in the Company’s current MD&A filed with the British Columbia Securities Commission. Forward-looking statements are necessarily based upon a number of estimates and assumptions. While such estimates and assumptions are considered reasonable by the management teams of Jemi, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks and accordingly may not occur as described herein or at all. Investors are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: Jemi Fibre Corp.  

ReleaseID: 430267

SEATTLE, WA / ACCESSWIRE / June 30, 2015 / Marijuana lab testing revenue could reach $850 million by 2020, according to a new report by GreenWave Advisors, an independent investment research and advisory firm serving the burgeoning cannabis industry. Driven by state-mandated cannabis testing requirements, investors may want to take a closer look at the lab testing segment of the industry as a potential investment opportunity.

According to the report from GreenWave Advisors:

“As individual states debate the efficacy of current legislative statutes or contemplate initial legalization referendums, lab testing requirements of cannabis products has become an increasing subject of concern and attention. Although the current governing statutes regarding legalized marijuana uses vary in great degrees from state to state, one common theme that has emerged is the increased awareness on the part of legislators and health officials, as well as cultivators and laboratories, of the critical importance of product testing and quality assurance.”

Cannabis testing is a relatively new phenomenon. In fact, Colorado had no protocols in place when the state first legalized marijuana. The program was only established about a year ago when a series of overdoses on edibles made the news. Similarly, Washington State didn’t introduce its cannabis testing requirements until 2013 when recreational cannabis became legal, even though medical cannabis had been used since 1998.

DigiPath Inc. (OTCQB: DIGP) is one of the few publicly traded cannabis laboratories. With one of just two labs in Nevada, the company has already signed an agreement with a dispensary (Euphoria Wellness) to test for unsafe levels of contaminants like heavy metals, microbes, mycotoxins, pesticides, and solvents that can exacerbate health issues. Unfortunately, these dangerous chemicals have been commonplace in cannabis nationwide.

With over 400 medicinal compounds found in the cannabis plant, it’s no wonder that so many states are requiring lab testing as a critical step in the seed-to-sale process. Only eight states of the 23 that have permitted medical marijuana require testing now, but five additional states are exploring testing legislation and that number is likely to expand moving forward as more states approve the drug and realize the potential hazards that exist.

In a recent article from Smithsonian.com, Andy LaFrate of Charas Scientific, who operates one of only eight labs in Colorado said, “It’s pretty startling just how dirty a lot of this stuff is… There’s a stereotype, a hippy kind of mentality, that leads people to assume that growers are using natural cultivation methods and growing organically… That’s not necessarily the case.”

For investors, cannabis laboratories represent an opportunity to capitalize on a growing sector without all of the regulatory red tape or risk associated with “pure” marijuana plays. Unlike Cannabis Science Inc. (OTC: CBIS), which is exploring clinical compounds, Mcig Inc. (OTC: MCIG), which focuses on vaporizer products, or MedBox Inc. (OTC: MDBX), which focuses on dispensary machines, DigiPath is well-positioned to meet an immediate regulator-driven demand for testing services.

A company like DigiPath Inc. (OTCQB: DIGP) is well suited to take advantage of this growing industry with their existing lab, trusted scientific team, and experienced management professionals.

To learn more about DigiPath Inc. please visit their website at http://www.digipath.com.

Or visit CannabisFN’s profile at http://www.cannabisfn.com/mdc/digipath-inc/. To learn more about Digipath Labs, please visit, http://www.digipathlabs.com.

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Important factors that could cause these differences include, but are not limited to, the demand for the company’s services and the company’s ability to execute its business plan. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claim to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, has been compensated for its services in the form of cash and equity securities by DigiPath. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

SOURCE: Cannabis Financial Network

ReleaseID: 430248

TORONTO, ON / ACCESSWIRE / June 30, 2015 / The Canadian Bioceutical Corporation (TSX Venture: BCC) (“BCC” or the “Company”) is pleased to announce that it has entered into a consultancy agreement with Dr. Miles Thompson, B.Sc, Ph.D. to advise and assist the Company in the development of its nutraceutical products, including derivatives and concentrates of cannabinoid-based medicinals.

Dr. Thompson served as a Clinical Research Associate at North York General Hospital in Toronto and initiated the study of cannabinoids in epilepsy at the Department of Pharmacology and Toxicology at the University of Toronto. He has extensive experience in the design and implementation of clinical trials administered by Health Canada.

Starting in May 2013, Dr. Thompson managed in vivo testing of cannabidiol in animal models of epilepsy at the Department of Pharmacology at the University of Toronto; a proof of principal necessary for human clinical trials. He has demonstrated his strong expectation of the efficacy of cannabinoids to treat various medical conditions and brings a keen familiarity and understanding of the research studies being conducted globally.

With over 40 publications in various journals and several awards to his credit, including ones from Epilepsy Canada and the Canadian Institutes of Health Research, Dr. Thompson brings a wealth of knowledge and relationships that can assist BCC in the development and testing of new and advanced natural health products and will be our principal liason in BCC’s ongoing collaboration with its Israel-based research partner, Cannabliss Inc.

“We welcome Dr. Thompson’s assistance in the development of new naturopathic products, especially those based on marijuana and hemp extracts and derivatives. There is great promise that the scientific community will use the active ingredients in marijuana and hemp to add to the wellness of people all over the world without the harmful side effects associated with many existing pharmaceutical treatments,” states Scott Boyes, BCC’s CEO. “These new products can be manufactured here in Canada and exported or licensed around the world as countries continue to amend and relax regulations in favour of medical marijuana use. We believe this will present new revenue opportunities for our company and create new value for our stakeholders.”

Additional details in relation to BCC’s plan to enter into the medical marijuana sector may be found in the company’s two (2) News Releases of January 7, 2015 with the most recent update provided in BCC’s News Release of May 11, 2015.

About The Canadian Bioceutical Corporation

BCC, formerly Allegiance Equity Corporation, is an Ontario corporation that, for over two decades has been developing unique standardized mass-market nutraceutical products for the treatment of common ailments where present pharmaceutical treatments and over-the-counter products fail to meet the needs of patients. BCC has targeted markets having clearly identified product deficiencies and dissatisfied consumers afflicted with a variety of medical conditions. BCC obtains regulatory approval and patents for these unique compounds and formulations and may produce and distribute or license its products for royalty revenues.

BCC’s principal brands are CinG-X(TM), Reliéva(TM), and Psorberine(TM) and FertaMax(TM). Additionally BCC, through its wholly-owned subsidiary BioCannabis Products Ltd. and, subsequent to receiving its MMPR license from Health Canada and the potential revision of the related regulations, intends to develop and market a series of new cannabis-based branded medicinal products to address this rapidly-evolving market.

Investors should be aware that companies cannot legally conduct a medical marijuana business without a license from Health Canada and that there is significant time and cost required to obtain such a license. As a publicly-traded company publicizing its intention to enter the medical marijuana industry, BCC urges potential investors in any company in this sector, to become familiar with the required resources and the related risks, costs implications and time required before a company will be able to begin licensed operations. There is no assurance that any company announcing its intent to enter the medical marijuana industry will be successful in obtaining a license or in creating shareholder value.

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Transaction and BCC’s objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in BCC’s public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although BCC believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, BCC disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the Policies of the Exchange) accepts responsibility of the adequacy or accuracy of this release.

For further information please contact:

Scott Boyes, President and CEO, The Canadian Bioceutical Corporation
scott@canadianbioceutical.com
(416) 840-4703

SOURCE: The Canadian Bioceutical Corporation

ReleaseID: 430266

LAS VEGAS, NV / ACCESSWIRE / June 30, 2015 / Methes Energies International Ltd. (NASDAQ: MEIL), announced that it has entered into agreements with certain institutional investors for a registered direct placement of approximately $1,250,000 of common stock at a price of $0.5435 per share.

In addition, the Company will issue to the investors warrants to purchase an aggregate of 1,781,292 shares of common stock (approx. 77% warrant coverage). The warrants have an exercise price of $0.882 per share and are exercisable beginning 6 months following their issuance, and expire five and one-half (5.5) years from closing.

The offering is expected to close on or about June 30, 2015, subject to satisfaction of customary closing conditions.

Chardan Capital Markets, LLC, acted as the sole placement agent for the transaction.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-195271), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on May 14, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC’s website at http://www.sec.gov.

About Methes Energies International Ltd.

Methes Energies International Ltd. is a renewable energy company that offers a variety of products and services to biodiesel fuel producers. Methes also offers biodiesel processors that are unique, truly compact, fully automated state-of-the-art and continuous flow that can run on a wide variety of feedstocks. Methes markets and sells biodiesel fuel produced at its 13 MGY facility in Sombra, Ontario, to customers in the U.S. and Canada, as well as providing multiple biodiesel fuel solutions to its clientele. Among its services are selling commodities to its network of biodiesel producers, selling their biodiesel production and providing clients with proprietary software to operate and control their processors. Methes also remotely monitors the quality and characteristics of its clients’ production, upgrades and repairs their processors and advises clients on adjusting their processes to use varying feedstock to improve the quality of their biodiesel. For more information, please visit www.methes.com.

Forward-looking Statements

This press release contains forward-looking statements regarding future events and financial performance. In some cases, you can identify these statements by words such as “may,” “might,” “will,” “should,” “except,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” the negative of these terms and other comparable terminology. These statements involve a number of risks and uncertainties and are based on numerous assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. There are or may be important factors that could cause our actual results to materially differ from our historical results or from any future results expressed or implied by such forward looking statements. These factors include, but are not limited to, those discussed under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended November 30, 2014, filed on March 11, 2015, which is available at the U.S. Securities and Exchange Commission website at www.sec.gov. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

###

Contacts:
Methes Energies International Ltd.
Michel G. Laporte, Chairman and CEO
702-932-9964

SOURCE: Methes Energies International Ltd.

ReleaseID: 430265

VANCOUVER, BC / ACCESSWIRE / June 30, 2015 / Electra Stone Ltd. (TSX Venture: ELT) (FSE: 44E1.F) (the “Company” or “Electra”) is pleased to announce the commencement of a 90 day prospecting program on its Nephrite Jade (“Jade”) projects near Dease Lake, British Columbia. The program will focus on new and known areas of Jade mineralization with the goal of identifying jade exploration targets for the 2016 season. The program will initially be focused on Electra’s recently acquired Polar Placer Project but will also include prospecting on regional opportunities and other Electra Stone Jade Claims within the BC Jade Mining Region.

John Costigan, President and CEO commented “We are very excited to execute on the first stage of our Jade strategy and look forward to continuing Electra’s development in the BC Jade industry.”

About The Polar Jade Project

The Polar Placer Jade Project is situated approximately 40 km east of the Town of Dease Lake, British Columbia, accessible along the Boulder Creek Mining Trail and approximately 1 km north of the Polar Jade(TM) Mine, one of Canada’s premier Jade mining operations. The famous gem-grade discovery at the Polar Mine secured Canadian Jade’s fame as a world class gemstone producer.

About Electra Stone

Electra Stone Ltd. is a mining company specializing in the development of and exploration for Nephrite Jade and industrial minerals. The Company is in the process of mining the Apple Bay aluminum silicate quarry located on Vancouver Island near Port Hardy, British Columbia. Electra has also recently entered into Nephrite Jade exploration in British Columbia. Total sales and price of B.C. Nephrite Jade have reportedly increased significantly over the past several years according to private producers. Increased interest in Nephrite Jade in South-East Asian countries, specifically China is the primary reason for the rise in demand.

For further information on Electra Stone Ltd. please visit www.electrastone.com.

Or contact: Tyler Lowes 604-681-1568.

On behalf of the Board of Directors,

“John Costigan”
President and Director

Forward Looking Statement

This document may contain or refer to forward-looking information based on current expectations, including, but not limited to timing of mineral resource estimates, future exploration or project development programs and the impact on the Company of these events. Forward –looking statements in this news release include completion of a financing and the issuance of securities. Forward information is subject to significant risks and uncertainties, as actual results may differ materially from forecasted results. Forward-looking information is provided as of the date hereof and we assume no responsibility to update, or revise them to reflect new events or circumstances. For a detailed list of risks and uncertainties as it relates to Electra Stone Ltd., please refer to the Company’s Annual Financials filed with SEDAR.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents herein.

SOURCE: Electra Stone Ltd.

ReleaseID: 430257